Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study describes a 15-year-old girl with a Sertoli–Leydig cell tumor who showed high androgen levels and steroidogenic responses similar to patients with polycystic ovary syndrome before surgery.

This study found that women with polycystic ovary syndrome have more pronounced metabolic alterations and higher androgen levels compared to women with eumenorrheic hyperandrogenism, suggesting EuHyperA may be a milder form of PCOS.

This case series observed the efficacy of GnRH analogues in diagnosing and treating various forms of ovarian hyperandrogenism, illustrating their role in symptom management without surgery, particularly for benign conditions and refractory androgen excess.

In this study, Buserelin nasal spray significantly reduced hirsutism scores and suppressed ovarian steroid secretion in women with non-adrenal hirsutism over six months, with effects lasting post-treatment.

In this study, transgender adolescents treated with testosterone for a median of 12 months experienced effective virilization, including voice deepening and increased hair growth, but also showed decreased HDL cholesterol and BMD z-scores, and increased hematocrit, with no short-term safety issues reported.

This report describes two cases of postmenopausal hyperandrogenism where GnRH analogue use suggested an ovarian source of excess androgens, leading to a diagnosis of benign ovarian tumors.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This article reports two cases where ovarian hyperthecosis caused hyperandrogenism in postmenopausal women, confirmed by imaging and resolved after bilateral oophorectomy.

In this case report, a 25-year-old transgender woman on testosterone-blocking therapy developed generalised hypertrichosis after starting ciclosporin for severe plaque psoriasis, illustrating that ciclosporin can induce this side effect even under androgen suppression.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This study describes a postmenopausal woman's diagnosis with ovarian hyperthecosis, confirmed by a GnRHa test normalizing testosterone, highlighting hormone therapy as a therapeutic option when surgery is not feasible.

In this case report, a 55-year-old postmenopausal woman was diagnosed with ovarian hyperthecosis as the cause of her hyperandrogenism after detailed hormonal and imaging investigations, which was successfully treated with bilateral salpingo-oophorectomy, leading to symptom improvement and normalized testosterone levels.

This study found that women treated with GnRHa for central precocious puberty had a higher prevalence of polycystic ovary syndrome in adulthood compared to those with isolated premature thelarche.

This article discusses diagnostic guidelines for PCOS, emphasizing the use of the Rotterdam criteria and recommending clomiphene citrate as the first-line treatment for ovulation induction; it reports no new clinical results.

This article reviews existing knowledge on postmenopausal hyperandrogenism and highlights diagnostic challenges, reporting no new clinical results.

This review outlines a diagnostic approach for identifying non-PCOS pathology in women with androgen excess, emphasizing the importance of clinical history and biochemical phenotyping but reports no new clinical results.

This review discusses the complexities and factors influencing the management of precocious puberty in children, concluding that genetic influences are more significant than environmental ones. It reports no new research findings.

This review discusses medical interventions that reproductive health experts can provide to transgender and gender diverse youth and reports no new clinical results.

In this case study, laparoscopic bilateral salpingo-oophorectomy was associated with reduced androgen levels and partial reversal of male-pattern hair loss in a postmenopausal woman with ovarian hyperandrogenism.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

This study found that oral contraceptives effectively suppressed hyperandrogenemia in most patients with hyperandrogenic-insulin-resistant acanthosis nigricans syndrome, though GnRH-a therapy was beneficial for those not responding initially.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

This review discusses hormonal therapies for acne related to endocrine disorders and provides practical guidelines for managing hormonally influenced acne in clinical practice, but reports no new clinical results.

This review discusses female hyperandrogenism, detailing diagnostic criteria and treatment options without reporting new study results; it emphasizes improving health and quality of life for affected women.

This study found that continuous use of loop diuretics may double the rate of bone loss in elderly men compared to intermittent or non-use.

This study reported that treatment with gonadotropin-releasing hormone analogs and cross-sex hormones appears appropriate for carefully selected youth with gender dysphoria, but long-term safety needs further investigation.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.